Stada already had two interested buyers in the mix as of earlier this week. And now, it’s got three.

It’s no secret that Sanofi has struggled of late at the dealmaking table. But why? The deal prospectus from former target Actelion buyer J&J offers some…

Analysts recently sized up Bristol-Myers as a takeover target. Now, word has it that Roche, Novartis and Pfizer are actively looking at a buy. But a megamerger…

Last year, Stada weighed a buyout to fend off an activist shareholder. Now, nearly six months after a proxy battle victory, it may find itself in a bidding war.

If you’re looking for new drama at Sanofi this year, you might just be disappointed. The French drugmaker said Wednesday it’s expecting no big financial swings…

CEO John Milligan was asked to ponder his $30 billion in 2016 revenue—and answer this key question: Can you "grow company without an acquisition?”

As it gets ready to announce earnings after the market closes today, Gilead is trading on Wall Street at less than seven times what analysts estimate it will…

Pfizer’s execs have said they’re not going to pause on dealmaking to wait for U.S. tax reform to free up cash. They may have another plan to drum up M&A…

BMS cut its 2017 guidance, but its I-O franchise remains strong—and one analyst suggests setbacks plus value could tag the company as a takeover target.

M&A